Venous thromboembolism (VTE) is a major health concern associated with significant morbidity and mortality. Critically ill patients are at an increased risk of VTE compared to general medical patients due to unique risk factors: prolonged immobilization, invasive lines and devices, certain medications, and acquired thrombophilia. Furthermore, VTE in the critically ill is associated with increased duration of mechanical ventilation, increased length of intensive care unit and hospital stay, and a trend toward increased mortality. Clinical practice guidelines therefore recommend VTE prophylaxis with either subcutaneous heparin or low-molecular-weight heparin for all critically ill patients without contraindication. Yet, many patients will develop VTE despite appropriate pharmacologic prophylaxis, which has led to interest in risk-stratifying critically ill patients for more aggressive prophylaxis strategies. Recent research identified patients at highest risk of failure of thromboprophylaxis and provided insight into the pathophysiologic mechanisms. Obesity and the receipt of vasopressors are 2 risk factors consistently identified in observational studies; further clinical data support decreased absorption of anticoagulant administered via the subcutaneous route as the likely mechanism behind thromboprophylaxis failure in these patient populations. Several studies have investigated novel thromboprophylaxis strategies to circumvent pharmacokinetic limitations in patients who are obese or on vasopressors: increased fixed-dose, weight-based subcutaneous, or continuous intravenous infusion of a prophylactic dose of anticoagulant has shown promise in limited studies; however, the results have yet to demonstrate superiority compared to current standard-of-care. This review discusses observational studies identifying patients at risk of thromboprophylaxis failure and critiques clinical studies evaluating novel thromboprophylaxis strategies in high-risk, critically ill patients with a focus on their limitations. Future studies are currently being conducted that will provide further guidance into the appropriate use of individualized thromboprophylaxis.
SilversteinMDHeitJAMohrDNPettersonTMO’FallonWMMeltonLJIII. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–593.
2.
AndersonFAJrWheelerHBGoldbergRJ, et al.A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933–938.
3.
HeitJASpencerFAWhiteRH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14.
4.
BellEJLutseyPLBasuS, et al.Lifetime risk of venous thromboembolism in two cohort studies. Am J Med. 2016;129(3):339.e19–e26.
5.
HeitJAMeltonLJIIILohseCM, et al.Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001;76(11):1102–1110.
6.
KearonC. Natural history of venous thromboembolism. Circulation. 2003;107(23 suppl 1):I22–I30.
7.
EsmonCT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev. 2009;23(5):225–229.
8.
SevittS. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol. 1974;27(7):517–528.
9.
EngelmannBMassbergS. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34–45.
10.
TsaiAWCushmanMRosamondWDHeckbertSRPolakJFFolsomAR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162(10):1182–1189.
LevitanNDowlatiARemickSC, et al.Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78(5):285–291.
13.
ChewHKWunTHarveyDZhouHWhiteRH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464.
14.
CushmanM. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62–69.
15.
SeligsohnULubetskyA. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222–1231.
16.
BarbarSNoventaFRossettoV, et al.A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450–2457.
17.
ObiATPannucciCJNackashiA, et al.Validation of the caprini venous thromboembolism risk assessment model in critically ill surgical patients. JAMA Surg. 2015;150(10):941–948.
18.
HeitJACrusanDJAshraniAAPettersonTMBaileyKR. Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood. 2017;130(2):109–114.
19.
HeitJASilversteinMDMohrDNPettersonTMO’FallonWMMeltonLJIII. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159(5):445–453.
20.
ComessKADeRookFARussellMLTognazzi-EvansTABeachKW. The incidence of pulmonary embolism in unexplained sudden cardiac arrest with pulseless electrical activity. Am J Med. 2000;109(5):351–356.
21.
AlikhanRPetersFWilmottRCohenAT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol. 2004;57(12):1254–1257.
22.
HeitJAMohrDNSilversteinMDPettersonTMO’FallonWMMeltonLJIII. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6):761–768.
23.
SchulmanSLindmarkerPHolmstromM, et al.Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4(4):734–742.
24.
StainMSchonauerVMinarE, et al.The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost. 2005;3(12):2671–2676.
25.
PengoVLensingAWPrinsMH, et al; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–2264.
26.
SpyropoulosACAndersonFAJrFitzGeraldG;IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706–714.
OrtelTL. Acquired thrombotic risk factors in the critical care setting. Crit Care Med. 2010;38(2 suppl):S43–S50.
29.
HirschDRIngenitoEPGoldhaberSZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA. 1995;274(4):335–337.
30.
MarikPEAndrewsLMainiB. The incidence of deep venous thrombosis in ICU patients. Chest. 1997;111(3):661–664.
31.
CookDCrowtherMMeadeM, et al.Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005;33(7):1565–1571.
32.
ShorrAFWilliamsMD. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost. 2009;101(1):139–144.
33.
KaplanDCasperTCElliottCG, et al.VTE incidence and risk factors in patients with severe sepsis and septic shock. Chest. 2015;148(5):1224–1230.
34.
CrowtherMACookDJGriffithLE, et al.Deep venous thrombosis: clinically silent in the intensive care unit. J Crit Care. 2005;20(4):334–340.
35.
CookDMeadeMGuyattG, et al; Canadian Critical Care Trials Group. Clinically important deep vein thrombosis in the intensive care unit: a survey of intensivists. Crit Care. 2004;8(3):R145–R152.
36.
GriffithLGuyattGWalterS. Attributable morbidity and mortality of DVT. Crit Care Med. 2008;35:A628.
37.
MalatoADentaliFSiragusaS, et al.The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus. 2015;13(4):559–568.
38.
McLeanJ. The thromboplastic action of cephalin. Am J Physiol. 1916;41:250–257.
39.
BrinkhousK. The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin. Am J Physiol. 1936;125:683–687.
40.
WesslerSYinET. Theory and practice of minidose heparin in surgical patients. A status report. Circulation. 1973;47(6):671–676.
41.
KakkarVVCorriganTSpindlerJ, et al.Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. Lancet. 1972;2(7768):101–106.
42.
Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 1975;2(7924):45–51.
43.
HampsonWGHarrisFCLucasHK, et al.Failure of low-dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. Lancet. 1974;2(7884):795–797.
44.
GruberUFDuckertFFridrichRRemJTorhorstJ. Prevention of fatal postoperative pulmonary embolism by low-dose heparin. Lancet. 1977;1(8017):898.
45.
RuizAJHillSLBerryRE. Heparin, deep venous thrombosis, and trauma patients. Am J Surg. 1991;162(2):159–162.
BrozovicMStirlingYAbboshJ. Plasma heparin levels after low dose subcutaneous heparin in patients undergoing hip replacement. Br J Haematol. 1975;31(4):461–466.
48.
PollerLTabernerDASandilandsDGGalaskoCS. An evaluation of APTT monitoring of low-dose heparin dosage in hip surgery. Thromb Haemost. 1982;47(1):50–53.
49.
LeyvrazPFRichardJBachmannF, et al.Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 1983;309(16):954–958.
50.
GreenDLeeMYItoVY, et al.Fixed- vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. JAMA. 1988;260(9):1255–1258.
51.
TabernerDAPollerLThomsonJMLemonGWeighillFJ. Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery. Br J Surg. 1989;76(9):933–935.
52.
HirshJ. Heparin. N Engl J Med. 1991;324(22):1565–1574.
ColwellCWJrSpiroTETrowbridgeAA, et al.Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 1994;76(1):3–14.
55.
GeertsWHJayRMCodeKI, et al.A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335(10):701–707.
56.
LeyvrazPFBachmannFHoekJ, et al.Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991;303(6802):543–548.
57.
Falck-YtterYFrancisCWJohansonNA, et al.Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e278S–e325S.
58.
RogersFBCipolleMDVelmahosGRozyckiGLuchetteFA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma. 2002;53(1):142–164.
59.
CadeJF. High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982;10(7):448–450.
60.
FraisseFHolzapfelLCoulandJM, et al.Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Resp Crit Care Med. 2000;161(4 pt 1):1109–1114.
61.
DeARoyPGargVKPandeyNK. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinolysis. 2010;21(1):57–61.
62.
PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, CookDMeadeMGuyattG, et al.Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305–1314.
63.
KahnSRLimWDunnAS, et al.Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e195S–226S.
LouisSGSatoMGeraciT, et al.Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. JAMA Surg. 2014;149(4):365–370.
66.
VoilsSACarlsonA. Association of deep-vein thrombosis (DVT) with missed doses of prophylactic antithrombotic medications in ICU patients: a case-control study. Annals Pharmacother. 2014;48(10):1294–1297.
67.
CookDDouketisJMeadeM, et al; Canadian Critical Care Trials Group. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care. 2008;12(2):R32.
68.
IbrahimEHIreguiMPrenticeDShermanGKollefMHShannonW. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med. 2002;30(4):771–774.
69.
HanifyJMDupreeLHJohnsonDWFerreiraJA. Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis. J Crit Care. 2017;37:206–210.
70.
LimWMeadeMLauzierF, et al; PROphylaxis for ThromboEmbolism in Critical Care Trial Investigators. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med. 2015;43(2):401–410.
71.
WelsbyIOrtelTL. Is it time for individualized thromboprophylaxis regimens in the ICU?Crit Care Med. 2015;43(2):500–501.
72.
VelmahosGCNigroJTatevossianR, et al.Inability of an aggressive policy of thromboprophylaxis to prevent deep venous thrombosis (DVT) in critically injured patients: are current methods of DVT prophylaxis insufficient?J Am Coll Surg. 1998;187(5):529–533.
73.
KroonCde BoerAKroonJMSchoemakerHCvan den MeerFJCohenAF. Influence of skinfold thickness on heparin absorption. Lancet. 1991;337(8747):945–946.
74.
FrederiksenSGHedenbroJLNorgrenL. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg. 2003;90(9):547–548.
75.
LudwigKPSimonsHJMoneMBartonRGKimballEJ. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Annals Pharmacother. 2011;45(11):1356–1362.
76.
FreemanAHornerTPendletonRCRondinaMT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol. 2012;87(7):740–743.
77.
RondinaMTWheelerMRodgersGMDraperLPendletonRC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res. 2010;125(3):220–223.
78.
WangTFMilliganPEWongCADealENThoelkeMSGageBF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111(1):88–93.
79.
JoyMTharpEHartmanH, et al.Safety and efficacy of high-dose unfractionated heparin for prevention of venous thromboembolism in overweight and obese patients. Pharmacotherapy. 2016;36(7):740–748.
80.
BeallJWoodruffAHempelCWovkulichMZammitK. Efficacy and safety of high-dose subcutaneous unfractionated heparin prophylaxis for the prevention of venous thromboembolism in obese hospitalized patients. Hosp Pharm. 2016;51(5):376–381.
81.
SamuelSIluonakhamheEKAdairE, et al.High dose subcutaneous unfractionated heparin for prevention of venous thromboembolism in overweight neurocritical care patients. J Thromb Thrombolysis. 2015;40(3):302–307.
82.
RobertsDJHallRI. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. 2013;9(9):1067–1084.
83.
JochbergerSMayrVLucknerG, et al.Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care. 2005;9(5):R541–R548.
84.
Dorffler-MellyJde JongeEPontAC, et al.Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002;359(9309):849–850.
85.
HelvizYDzigivkerIRaveh-BrawerDHerschMZevinSEinavS. Anti-factor Xa activity of prophylactic enoxaparin regimens in critically ill patients. Isr Med Assoc J. 2016;18(2):108–113.
86.
PriglingerUDelle KarthGGeppertA, et al.Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill?Crit Care Med. 2003;31(5):1405–1409.
87.
MayrAJDunserMJochbergerS, et al.Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res. 2002;105(3):201–204.
88.
RobinsonSZincukAStromTLarsenTBRasmussenBToftP. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care. 2010;14(2):R41.
89.
CostantiniTWMinEBoxK, et al.Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg. 2013;74(1):128–33; discussion 134-135.
90.
RobinsonSZincukALarsenUL, et al.A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial. Crit Care. 2013;17(2):R75.
91.
MalinoskiDJafariFEwingT, et al.Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma. 2010;68(4):874–880.
92.
KoAHaradaMYBarmparasG, et al.Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma. JAMA Surg. 2016;151(11):1006–1013.
93.
F ShepherdMRosboroughTKSchwartzML. Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. Obes Surg. 2004;14(5):601–605.
94.
QuebbemannBAkhondzadehMDallalR. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes Surg. 2005;15(9):1221–1224.
95.
ChengSSNordenholzKMateroD, et al.Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Intensive Care Med. 2012;38(4):642–648.
96.
BounameauxHde MoerlooseP. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost. 2004;2(4):551–554.
97.
BrophyDFCarrMEJrMartinEJVenitzJGehrTW. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. J Clin Pharmacol. 2006;46(8):887–894.
98.
BolligerDSeebergerMDTanakaKA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev. 2012;26(1):1–13.
99.
ConnellyCRVanPYHartKD, et al.Thrombelastography-based dosing of enoxaparin for thromboprophylaxis in trauma and surgical patients: a randomized clinical trial. JAMA Surg. 2016;151(10):e162069.
100.
CohenATSpiroTEBullerHR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513–523.
101.
GoldhaberSZLeizoroviczAKakkarAK, et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167–2177.
102.
AndreozziGMBignaminiAADaviG, et al; SURVET Study Investigators. Sulodexide for the prevention of recurrent venous thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015;132(20):1891–1897.
103.
MackmanN. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914–918.
104.
BullerHRBethuneCBhanotS, et al; FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232–240.
105.
UndasABrummel-ZiedinsKEMannKG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost. 2014;111(3):392–400.
106.
GlynnRJDanielsonEFonsecaFA, et al.A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851–1861.
107.
HarrJNMooreEEChinTL, et al.Platelets are dominant contributors to hypercoagulability after injury. J Trauma Acute Care Surg. 2013;74(3):756–62; discussion 62-65.
108.
BrightonTAEikelboomJWMannK, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979–1987.
